Restricted accessResearch articleFirst published online 2025-07
Synergistic Antimicrobial Activity of Colistin and Amikacin with Zinc Oxide Nanoparticles and Their Posttranscriptional Regulation of mcr-1 Gene Expression in Colistin-Resistant Klebsiella pneumoniae
The bacteria Klebsiella pneumoniae is encapsulated, rod-shaped, nonmotile, and Gram-negative bacilli. K. pneumoniae causes a variety of illnesses. They express various virulence factors such as capsules, which are primary virulence factors responsible for the pathogenicity and protection of bacteria from phagocytosis, lipopolysaccharide, which act as external membranes of the bacteria; and fimbriae-І and ІІІ which promote the binding to biological surfaces like medical devices such as ventilators. K. pneumoniae’s resistance to cephalosporins (3rd and 4th generation), quinolones, carbapenem, and colistin is increasing. Colistin is the last trait to treat multidrug-resistant K. pneumoniae. The monotherapy is becoming ineffective to treat infections. Plasmid-borne genes called mcr-1 mediate colistin resistance, which is more prevalent. Colistin resistance and gene detection were done by using Epsilometry-test and conventional PCR, respectively. Amikacin was tested for synergism with colistin. Colistin with zinc oxide nanoparticle (NP) synergism was also tested. The properties of zinc oxide NPs are assessed by Fourier-transform infrared (FTIR), scanning electron microscope (SEM), and ultraviolet (UV) visible spectroscopy. Antibacterial activity of zinc oxide NPs was determined using the agar well diffusion method. In our study, we encourage combination drug therapy to treat the colistin-resistant K. pneumoniae. The synergistic activity of combined drugs was tested using checker-board technique. The results revealed that the synergistic activity of colistin combined with zinc oxide NPs and amikacin against colistin-resistant K. pneumoniae was found to be effective and can be further developed against the colistin resistant K. pneumoniae.
FalagasME, KasiakouSK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis, 2005; 40(9):1333–1341.
5.
WarrenHS, KaniaSA, SiberGR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob Agents Chemother, 1985; 28(1):107–112.
6.
LiuYY, WangY, WalshTR, et al.Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis, 2016; 16(2):161–168.
7.
HelanderIM, KatoY, KilpeläinenI, et al.Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem, 1996; 237(1):272–278.
8.
WangX, WangY, ZhouY, et al.Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-producing Klebsiella pneumoniae. Emerg Microbes Infect, 2018; 7(1):122.
9.
WangY, TianGB, ZhangR, et al.Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: An epidemiological and clinical study. Lancet Infect Dis, 2017; 17(4):390–399.
10.
YangYQ, LiYX, LeiCW, et al.Novel plasmid-mediated colistin resistance gene mcr-7.1 in Klebsiella pneumoniae. J Antimicrob Chemother, 2018; 73(7):1791–1795.
11.
KatoH, HamadaY. Amikacin therapy in Japanese paediatric patients: Narrative review. Int J Environ Res Public Health, 2022; 19(4):1972; doi: 10.3390/ijerph19041972
12.
GrimaldoOE, GarciaAR, MedinaDR, et al.Determination of neonatal hearing loss related to the use of amikacin in patients with neonatal sepsis through screening with otoacoustic emissions in the General Hospital of San Jose Iturbide, Guanajuato, Mexico. J Pediatr Perinatol Child Health, 2019; 03(02):061–068.
13.
PachaiappanR, RajendranS, ShowPL, et al.Metal oxide nanocomposites for bactericidal effect: A review. Chemosphere, 2021; 272:128607; doi: 10.1016/j.chemosphere.2020.128607
14.
AzamA, AhmedAS, OvesM, et al.Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: A comparative study. Int J Nanomedicine, 2012; 7:6003–6009.
15.
AgarwalH, MenonS, KumarSV, et al.Mechanistic study of the antibacterial action of zinc oxide nanoparticles synthesized using green route. Chemico-Biol Inter, 2018; 286:60–70; doi: 10.1016/j.cbi.2018.03.008
16.
BurmanU, SainiM, KumarP. Effect of zinc oxide nanoparticles on growth and antioxidant system of chickpea seedlings. Toxicol Environ Chem, 2013; 95(4):605–612; doi: 10.1080/02772248.2013.803796
17.
BarthalomewJW, MittewerT. A simplified bacterial strain. Stain Technol, 1950; 25:153.
18.
WayneP, Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25; 2015.
19.
Turlej-RogackaA, XavierBB, JanssensL, et al.Evaluation of colistin stability in agar and comparison of four methods for MIC testing of colistin. Eur J Clin Microbiol Infect Dis, 2018; 37(2):345–353; doi: 10.1007/s10096-017-3140-3
20.
Newton-FootM, SnymanY, MalobaMR, et al.Plasmid mediated mcr-1 colistin resistance in Escherichia coli and Klebsiella spp. clinical isolates from the Western Cape region of South Africa. Antimicrob Resist Infect Control, 2017; 6:78; doi: 10.1186/s13756-017-0234-8
21.
RebeloAR, BortolaiaV, KjeldgaardJS, et al.Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill, 2018; 23(6):17–00672; doi: 10.2807/1560-7917.ES.2018.23.6.17-00672
22.
GetieS, BelayA, Chandra ReddyAR, BelayZ. Synthesis and characterizations of zinc oxide nanoparticles for antibacterial applications. J Nanomed Nanotechno S, 2017; 8(004).
23.
KheshtiR, PourabbasB, MosayebiM, et al.In vitro activity of colistin in combination with various antimicrobials against Acinetobacter baumannii species, a report from South Iran. Infect Drug Resist, 2019; 12:129–135; doi: 10.2147/IDR.S182585
24.
GülerŞ, TorulD, Kurt-BayrakdarS, et al.Evaluation of antibacterial efficacy of Lawsonia inermis Linn (henna) on periodontal pathogens using agar well diffusion and broth microdilution methods: An in-vitro study. Biomedicine (Taipei), 2023; 13(3):25–30; doi: 10.37796/2211-8039.1411
25.
Stojowska-SwędrzyńskaK, ŁupkowskaA, Kuczyńska-WiśnikD, et al.Antibiotic heteroresistance in K. pneumoniae. Int J Mol Sci, 2021; 23(1):449; doi: 10.3390/ijms23010449
26.
LeeCR, LeeJH, ParkKS, et al.Antimicrobial resistance of hypervirulent K. pneumoniae: Epidemiology, hypervirulence-associated determinants, and resistance mechanisms. Front Cell Infect Microbiol, 2017; 7:483; doi: 10.3389/fcimb.2017.00483
27.
ChangCY, OngELC. Positive string test in hypervirulent Klebsiella pneumoniae liver abscess. Oxf Med Case Rep, 2022; 2022(4):omac035.
28.
MendesG, SantosML, RamalhoJF, et al.Virulence factors in carbapenem-resistant hypervirulent K. pneumoniae. Front Microbiol, 2023; 14:1325077; doi: 10.3389/fmicb.2023.1325077
29.
FicikJ, AndrezálM, DrahovskáH, et al.Carbapenem-resistant K. pneumoniae in COVID-19 era-challenges and solutions. Antibiotics (Basel), 2023; 12(8):1285; doi: 10.3390/antibiotics12081285
30.
da SilvaRM, TraebertJ, GalatoD. Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: A review of epidemiological and clinical aspects. Expert Opin Biol Ther, 2012; 12(6):663–671; doi: 10.1517/14712598.2012.681369
31.
RashaE, MonerahA, ManalA, et al.Biosynthesis of zinc oxide nanoparticles from Acacia nilotica (L.) extract to overcome carbapenem-resistant K. pneumoniae. Molecules, 2021; 26(7):1919; doi: 10.3390/molecules26071919
32.
MinaeianS, KhalesP, Hosseini-HosseinabadSM, et al.Evaluation of activity of zinc oxide nanoparticles on human rotavirus and multi-drug resistant Acinetobacter baumannii. Pharm Nanotechnol, 2023; 11(5):475–485; doi: 10.2174/2211738511666230504121506
33.
YuvarajA, PriyadharshiniR, KumarR, SindujaP. Anti-inflammatory and antifungal activity of zinc oxide nanoparticle using red sandalwood extract. Pharmacophore, 2023; 14(1):25–31.
34.
GeethaRV, RajaselinARS. Anti-diabetic and anti-microbial activity of aspalathus linearis and syzygium aromaticum formulation mediated zinc oxide nanoparticles. Med J Malaysia, 2025; 80:(Suppl 1):10–16.
35.
HarshithaVR, IlangovarIG, SureshV, PitchiahS, SivaperumalP. Synthesis of zinc oxide nanoparticles from Cymodocea serrulata leaf extract and their biological activities. Cureus, 2024; 16(3):e55521.
36.
ErfanA, YousifE, AlshanonAN, et al.Organotin(IV) complexes as promising potential drug candidates in the field of cancer chemotherapy: A narrative review. Al-Rafidain J Med Sci, 2023; 5:48–56; doi: 10.54133/ajms.v5i.146
37.
LemlemM, AkliluE, MohamedM, et al.Phenotypic and genotypic characterization of colistin-resistant Escherichia Coli with mcr-4, mcr-5, mcr-6, and mcr-9 genes from broiler chicken and farm environment. BMC Microbiol, 2023; 23(1):392; doi: 10.1186/s12866-023-03118-y
38.
IbadiF, YousifE, Al-AniA, et al.Organotin complexes with Schiff’s base ligands: Insights into their cytotoxic effects on lung cancer cells. J Umm Al-Qura Univ Appl Sci, 2024; doi: 10.1007/s43994-024-00170-w
39.
AulaS, LakkireddyS, KapleyA, et al.Route of administration induced in vivo effects and toxicity responses of Zinc Oxide nanorods at molecular and genetic levels. International Journal of Nano Dimension, 2018; 9(2):158–169.
40.
Brennan-KrohnT, PirontiA, KirbyJE. Synergistic activity of colistin-containing combinations against colistin-resistant enterobacteriaceae. Antimicrob Agents Chemother, 2018; 62(10):e00873-18; doi: 10.1128/AAC.00873-18
41.
FadwaAO, AlkoblanDK, MateenA, AlbaragAM. Synergistic effects of zinc oxide nanoparticles and various antibiotics combination against Pseudomonas aeruginosa clinically isolated bacterial strains. Saudi J Biol Sci, 2021; 28(1):928–935; doi: https://doi.org/10.1016/j.sjbs.2020.09.064
